Hospital participated in a multicenter acute stroke trial but enrolled only one patient out of 192 screened over 2 years; other centers had similar difficulty in patient recruitment. We analyzed our screening data to determine which enrollment criteria created difficulties in recruitment and whether the problem was attributable to any single criterion or to combinations of criteria. Six individual criteria were frequent causes for exclusion; however, >80% of the patients were excluded for multiple reasons. Consequently, modifying or eliminating any single criterion did not appreciably increase patient accrual. Only 17 of 210 possible pairs of criteria occurred with statistically significant frequency (/><0.05), and these were most likely random associations. Therefore, only by minimizing the number and stringency of enrollment criteria will patient accrual be at a level that allows the study to be completed in a timely manner with a fiscally reasonable number of centers. T he efficacy of new therapies for acute stroke can be assessed formally only by controlled clinical trials. However, one difficulty in conducting such trials has been patient accrual. For example, the recent Scandinavian multicenter hemodilution trial enrolled only 32% of 604 patients screened.
T he efficacy of new therapies for acute stroke can be assessed formally only by controlled clinical trials. However, one difficulty in conducting such trials has been patient accrual. For example, the recent Scandinavian multicenter hemodilution trial enrolled only 32% of 604 patients screened. 1 Other stroke studies have experienced even greater difficulties. After 980 patients were screened for a study of naftidrofuryl in acute cerebral infarction, only 100 (10.2%) met the enrollment criteria and were actually included in the study. 2 Another recent 4-year trial of intravenous heparin for acute partial stable thrombotic stroke enrolled only 7.4% of the screened patients. 3 Patient accrual was difficult in these studies in part because restrictive enrollment criteria have been devised to provide as homogeneous a population of stroke patients as possible. This is a reasonable approach since a given therapy may be targeted toward modifying only a specific aspect of stroke pathophysiology. While such homogeneity simplifies interpretation of results and increases the chance of detecting any beneficial effect of the new therapy on specific stroke types, these restrictive criteria can lead to difficulty in enrolling enough patients within a reasonable period and in generalizing the study results to the broader population of stroke patients.
Temple University Hospital (TUH) was involved recently in an acute stroke multicenter clinical trial of a calcium channel blocker that used restrictive enrollment criteria formulated to maximize homogeneity among patients. However, application of these criteria produced an unacceptably low patient enrollment. We describe the enrollment criteria and their successive revisions. The frequency with which each criterion alone and in combination prevented accrual of patients was analyzed. Based on this experience, we gained insights that should help in the design of future clinical trials.
Subjects and Methods
A multicenter clinical trial of a new calcium channel blocker in acute ischemic stroke was initiated in 1984. TUH was one of several study centers. Over 2 years, 192 patients admitted to TUH with diagnosed focal neurologic deficits consistent with acute stroke were screened using the enrollment criteria shown in Table 1 . The screening of patients was not continuous; there were interruptions during the 2-year interval while enrollment criteria were reviewed and revised to address the difficulty of enrolling patients. The rationale for selecting the various enrollment criteria have been reviewed elsewhere. •Cardiac exclusions were myocardial infarction <4 months, acute or noncompensated heart failure, complete heart block, ventricular arrhythmia, unstable angina, cardiac or carotid surgery s i month, blood pressure of > 190/110 or <90/60 mm Hg, or pulse of > 110/min or <50/min. tExclusionary concomitant medications were vasodilators, barbiturates, naloxone, /3-blockers, other calcium channel antagonists, dextrans including mannitol, anticoagulants, antiplatelet agents, corticosteroids, neuroleptics, antidepressants, and hypnotics. tDisallowed concomitant medications were vasodilators, naloxone, other calcium channel antagonists, dextrans including mannitol, corticosteroids and barbiturates other than short-acting; other medication allowed; 325 mg aspirin/day required in nonanticougulated patients.
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§Examples include amputations and other defects making assessment impossible.
Screening for acceptability was done by a member of the Neurology Department of TUH within a few hours after the patient was admitted to the hospital. The patient's clinical history was obtained, a neurologic examination was performed, the computed tomogram (CT scan) was reviewed, and laboratory studies were done. As the study progressed and accrual remained nil, individual enrollment criteria were modified, but often a given patient was excluded by multiple criteria. Therefore, modification of one or several criteria had disappointingly little effect on patient accrual.
The frequency with which sets of enrollment criteria were exclusionary was noted. In the sets containing two criteria, a x 2 test with 1 degree of freedom was used to determine which combinations occurred frequently enough to be statistically significant. Expected frequencies were calculated by assuming independence of the criteria and multiplying the proportion excluded by each criterion in the pair by the total number of patients.
Results
Ninety-four patients were screened using the initial enrollment criteria. Of these, all were excluded. Twenty-three patients (24%) were excluded because their stroke occurred >24 hours before our screening, but in none was time of screening the sole reason for disqualification. Evidence of a previous stroke by history, CT, or other prior neurologic deficit excluded 29 (31%) of the 94 screened, but previous stroke was the sole disqualifier in only four (4%). Medical conditions (e.g., blood pressure consistently >190 mm Hg systolic or >110 mm Hg diastolic, a disease affecting drug absorption or excretion) excluded 32 (34%); however, 31 of these 32 patients were also excluded on one or more additional criteria. Cardiac disease (congestive heart failure, atrial fibrillation, valvular heart disease, cardiac arrhythmias, or recent cardiac surgery) disqualified 26 of the 94 patients (28%); cardiac disease was the sole reason for exclusion of only two patients (2%). Concomitant medications excluded 28 (30%) of the 94 screened, but no patient was disqualified solely on the basis of concomitant medications. Among the 94 patients initially screened, only 14 (15%) were disqualified on a single enrollment criterion; thus, most patients had more than one reason for exclusion. In 27 (29%) there were two disqualifying factors; 19 (20%) had three and 11 (12%) had four disqualifying factors. In 23 patients (24%) there were five or more reasons for exclusion.
After 5 months of screening patients with no enrollments, six criteria were modified slightly to make them less restrictive (Table 1 , Revision 1). The lower age boundary was dropped from 40 to 35 years with no restriction placed on the upper boundary, the vascular territory affected by the stroke was extended to include the anterior cerebral artery (ACA), severity of the stroke was changed to exclude those with hemiplegia, patients with evidence of a previous contralateral stroke without residual defi- 
cits were included, of medical conditions only significant hepatic or renal disease were exclusionary, and the criterion for presence of heart disease was modified to allow enrollment of those with compensated congestive heart failure. Using the Revision 1 enrollment criteria, another 78 patients were screened, but again, none were enrolled. As with the initial enrollment criteria, multiple reasons for exclusion disqualified the majority of potential patients. The percent of these patients excluded by each Revision 1 criterion is shown in Table 1 . Thus, none of the six modifications in enrollment criteria of Revision 1 improved patient accrual. In retrospect, this might have been anticipated. For example, dropping the lower age boundary from 40 to 35 years would not be likely to improve patient recruitment since very few strokes occur in the 35-40-year-old age range. However, removing the upper limit did reduce the number of patients excluded by this criterion. Broadening the vascular territory affected to include the ACA territory did not permit us to enroll more patients as none of the initial 94 patients screened had been excluded on the basis of ACA territory strokes, and none of the 78 subsequent patients screened had ischemia confined to the ACA territory.
Since no patients were enrolled with Revision 1 criteria, additional changes in four more criteria were made (Table 1, Revision 2). Using Revision 2 criteria, another 20 patients were screened and one was enrolled. The enrollment of one patient after screening 192 with almost 2 years' work is obviously inefficient. Other centers participating in the trial had similar difficulty in enrolling patients. Therefore, a careful reconsideration of the enrollment criteria was clearly necessary.
In formulating reasonable rules for enrollment, the criteria must be considered in combination. Only 35 (18.3%) of the 192 patients in this study were excluded on a single criterion; most were excluded on multiple criteria (Table 2) . Table 3 gives the percentages excluded for each criterion Nonneurologic deficit was associated with significant gastrointestinal disease (p<0.01). However, in individually testing 210 possible combinations each at a nominal significance level of 0.05, one would anticipate up to 17 significant associations by chance alone (95% confidence interval 4-17) even if no significant association actually existed, if the combinations are independent; in fact, they are not independent. Since only 17 significant associations were found, we conclude that many combinations of enrollment criteria probably were simply random associations. Therefore, discarding or making a few criteria less restrictive would be unlikely to result in an appreciably increased enrollment.
After screening 192 acute stroke patients, recruitment for the clinical trial was temporarily suspended and new enrollment criteria were formulated in an effort to obtain criteria that would permit enrollment of enough patients to complete the trial within a reasonable time. The final criteria listed in Table 1 were formulated, and 71 more patients were screened; of these, 16 (23%) were accepted. This was clearly an improvement. Had these 16 patients been screened according to the previous three sets of criteria, only one would have been accepted under either the initial or Revision 1 criteria; all 16 would have been accepted under Revision 2 criteria. Therefore, with modification, the enrollment criteria more closely approximated the characteristics of ischemic stroke patients actually encountered in an acute-care hospital, and the efficiency of patient accrual increased from near zero to an acceptable level.
Discussion
Given the substantial loss of potential subjects resulting from the failure to meet enrollment criteria, a clinical trials investigator might be tempted to ask why any restrictions should be imposed on patient recruitment; however, on reflection it is clear that some restrictions are required. For example, one must match the expected action of the drug being tested with the pathophysiology of stroke. Since in this study calcium channel blockers are postulated to affect only acute stroke events, enrollment of only acute stroke patients was appropriate. However, the interval considered acute may vary. Since it takes time for a patient to reach the hospital, to undergo diagnostic tests, and to give informed consent, the interval of acceptability should not be too short. Almost one fourth of those we screened presented >24 hours after onset of the stroke. In the National Survey of Stroke, 5 35% of patients with ischemic strokes were hospitalized >24 hours and approximately 20% >48 hours after onset. On the other hand, if the interval of acceptability is too long, the beneficial effect of a new therapy may be obscured. For example, in a study of theophylline treatment for acute stroke, failure to observe a beneficial effect was attributed to a delay in enrollment of up to 46 hours after onset. 67 Another factor that restricts enrollment is the extent of the stroke. If the area of brain damaged is very small (e.g., a lacune), the patient may recover spontaneously. A recent hospital-based study found that 7.5% of stroke admissions were lacunar. 8 Large lesions may produce coma, which precludes evaluation by standardized scales usually included in a stroke clinical trial. Moreover, prognosis for survival in comatose patients is poor. When standard efficacy measures such as the Toronto Stroke Scale of the patients screened were excluded because of posterior circulation deficits, a percentage similar to that we excluded for failure to meet the territory inclusion criterion.
Ethical and safety considerations restrict recruitment, but few patients at our center were excluded for these reasons alone. Cardiac disease and medical conditions, when severe, usually exclude a patient. In the National Stroke Survey, 5 35% of patients with embolic stroke had valvular heart disease, and over half of all patients with ischemic strokes had chronic heart disease, atrial fibrillation, and other arrhythmias. We excluded 19% of the patients screened for cardiac disease under the initial, Revision 1, and Revision 2 criteria, but when the criterion was modified to exclude only those with acute or unstable heart disease, nine patients were excluded. Our experience compares with the 7% excluded for cardiac reasons in the Scandinavian Hemodilution Study. 1 It is necessary to exclude patients who must receive drugs the effects of which potentially confound those of the test drug, and in our study 21% of those patients screened under the initial, Revision 1, and Revision 2 criteria were excluded because of concomitant medications.
The above exclusions consider loss of patients according to individual criteria, but an important insight gained from our study was that modifying any one or even many criteria would have a much less salutary effect on recruitment of patients than would be anticipated from noting the proportion rejected when a specific criterion was considered alone. Only a few modifications led to an appreciable decline in the percentage excluded by an individual criterion (Table 1) . For example, removing the upper age boundary decreased exclusions because of that criterion, as did allowing previous contralateral stroke without residual deficit. Allowing compensated congestive heart failure and changes in disallowed concomitant medications decreased exclusions due to those criteria. Other changes, such as enlarging the vascular territory to include the ACA and allowing patients with plegia of one limb, did not appreciably change the percentage excluded by those criteria. Some criteria that were not modified showed fluctuations in the percentage excluded and probably reflect fluctuation in the characteristics of successive groups of patients who were screened.
Most patients were disqualified on more than one criterion so modification or elimination of many criteria was needed to capture a significant number of patients. However, elimination of exclusion criteria also reduces homogeneity of the study population, and compromises must be made. Strict enrollment criteria reduce the number of patients who can be enrolled in any given center, but this problem can be overcome by adding more centers. Of course, costs and variability in the study data increase with the addition of centers. Some indication of the costs of including various enrollment criteria can be determined from our study, and our experience can serve as a guideline in selecting criteria for future acute stroke trials. The number of patients excluded by various enrollment criteria should be calculated in other medical centers to assure that our experience was representative.
